02 November 2017
: Case report
Recurrent Thrombosis: A Case of Hereditary Thromboembolism
Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Congenital defects / diseases
Maria Concetta Giofrè1E*, Francesca Napoli1B, Daniela La Rosa1C, Alessia Caruso1G, Natascia Laganà1D, Lucia Orlando Settembrini2C, Antonino Saitta1F, Antonio Giovanni Versace1ADOI: 10.12659/AJCR.906035
Am J Case Rep 2017; 18:1157-1159
Abstract
BACKGROUND: Thrombophilia is a predisposition to thrombosis. Genetic causes include antithrombin III, protein C, protein S, factor V Leiden, prothrombin 20210A allele, and MTHFR mutations. Other genetic factors causing thrombosis and pulmonary embolism have been identified in recent studies, including 4G/4G polymorphism of the PAI-1 gene.
CASE REPORT: A patient with a personal and family history of recurrent thrombosis and pulmonary embolism was admitted to our Internal Medicine Department. After the most common acquired risk factors for thromboembolism were ruled out, the patient and her family members underwent genetic diagnostic testing. These tests showed homozygous 4G/4G polymorphism of the PAI-1 gene in 14 subjects, homozygous 4G/4G polymorphism of the PAI-1 gene and C677T/A1298C polymorphism of the MTHFR gene in 4 subjects, and heterozygous 4G/4G polymorphism of the PAI-1 gene and C677T/A1298C polymorphism of the MTHFR gene in 3 subjects. Afterwards, we initiated the administration of Rivaroxaban, with beneficial results.
CONCLUSIONS: No thrombotic recurrence has been observed in the patient since 2014. This case report shows the efficacy and superiority of Rivaroxaban over traditional anticoagulants in the treatment of hereditary thrombophilia. Further studies are clearly needed before Rivaroxaban can be recommended as a standard treatment in patients with inherited thrombophilia.
Keywords: Anticoagulants, Factor X, Polymorphism, Restriction Fragment Length
SARS-CoV-2/COVID-19
04 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934468
29 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936896
16 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936498
13 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936889
In Press
04 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936836
04 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934468
04 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936448
01 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936536
Most Viewed Current Articles
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
09 Feb 2022 : Case report
DOI :10.12659/AJCR.934744
Am J Case Rep 2022; 23:e934744